Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reductionTrial to adjudicate Anaptys’ contract ...

The first day of the summit presented Maharashtra’s larger development blueprint, which focuses on integrated infrastructure, ...

Codex now runs on GPT-5.5 hosted on Nvidia's GB200 NVL72 rack-scale systems. Nvidia says the systems deliver 35x lower cost ...

Regeneron will provide Otarmeni, its recently FDA-approved gene therapy for an ultra-rare form of genetic hearing loss, for ...

ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, today announces the appointment ...

Overall, TherVacB was found to be safe, well-tolerated, and highly immunogenic among the healthy study participants.

Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to ...

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger ...

Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. The Gaza Strip has ...

AnaptysBio has spun off its biopharma pipeline into First Tracks Biotherapeutics, shifting to a royalty-focused, virtual ...

There will be little to celebrate on World Malaria Day on 25 April. Global malaria cases, which stood at 238 million in 2018, ...

The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...